Menu Search
Equities

InterCure Ltd

INCR:NMQ

InterCure Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.36
  • Today's Change0.07 / 3.06%
  • Shares traded35.37k
  • 1 Year change+12.92%
  • Beta--
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

  • Revenue in ILS (TTM)355.55m
  • Net income in ILS-61.96m
  • Incorporated1994
  • Employees270.00
  • Location
    InterCure LtdMedinat HaYehudim 85HERZLIYA 4676670IsraelISR
  • Phone+972 732207002
  • Fax+972 97680244
  • Websitehttps://www.intercure.co/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.